The DOI matches its Crossref record; 115 of the 117 references it cites were found in a registry or an index.
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Abstract
Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this context, the inhalation route is advantageous for the pulmonary delivery of anti-TB drugs and requires lower doses to achieve therapeutic effects. The pulmonary delivery of drugs is a convenient and effective approach for the treatment of TB.202”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [202]
Citations
Cites
Inhaling medicines: delivering drugs to the body through the lungs
Patton, J. S., & Byron, P. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2153 · Cited by 1,370
Xu, J., Kochanek, K. D., Murphy, S. L., & Tejada‐Vera, B. (2010) · PubMed · Cited by 650
The Lungs as a Portal of Entry for Systemic Drug Delivery
Patton, J. S., Fishburn, C. S., & Weers, J. G. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-049ta · Cited by 564
Nanomedicine in pulmonary delivery
Mansour, H. M., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 497
Self-citationOGILVIE, R. I. (1983) · PubMed Central · Cited by 395
Nanoparticle formulations in pulmonary drug delivery
Bailey, M. M., & Berkland, C. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20140 · Cited by 302
Rijnders, B. J. A., Cornelissen, J. J., Slobbe, L., Becker, M. J., Doorduijn, J. K., Hop, W. C. J., Ruijgrok, E. J., Löwenberg, B., Vulto, A. G., Lugtenburg, P. J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/586739 · Cited by 284
Zakharian, T. Y., Seryshev, A. B., Sitharaman, B., Gilbert, B. E., Knight, V., & Wilson, L. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0546525 · Cited by 277
Heijerman, H. G. M., Westerman, E. M., Conway, S., & Touw, D. J. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Nanomedicine for respiratory diseases
Pison, U., Welte, T., Giersig, M., & Groneberg, D. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.068 · Cited by 262
Research works printed but not linked: 4
- Hickey AJ, Mansour HM (2009) Chapter 5: delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J (eds) Modern pharmaceutics, vol 2, 5th edn. Taylor and Francis, New York, pp 191–219
- Perrie Y, Rades T (2010) Pharmaceutics—drug delivery and targeting. Pharmaceutical Press, London
- Darwis Y, Kellaway IW (2002) The lyophilisation and aerosolisation of liposomes for pulmonary drug administration. STP Pharma Sci 12(2):91–96
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (2008) Pharmacotherapy: a pathophysiological approach, 7th edn. McGraw-Hill Medical, New York
Cited by
Sorted by citations
Items 101–148 of 148
Beeraka, N. M., Zhou, R., Wang, X., R, H. V. P., Kumar, T. P., Liu, J., Greeshma, M. V., Mandal, S. P., Gurupadayya, B., & Fan, R. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s364693 · Cited by 5
Ochowiak, M., Matuszak, M., & Włodarczak, S. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1358274 · Cited by 5
Hasanin, A. (2014) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000219 · Cited by 5
Hillery, A., & Park, K. (2016) · CRC Press eBooks · doi:10.1201/9781315382579-12 · Cited by 5
Zhang, D., Zhao, H., Li, P., Wu, X., & Liang, Y. (2024) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2023.0025 · Cited by 4
Ong, H. X., Traini, D., & Young, P. M. (2024) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2024.29112.hxo · Cited by 4
Liposome-Based Drug Delivery—A New Therapeutic Paradigm
Shetye, L. A., Sherlekar, A., & Mendhulkar, V. D. (2023) · Studies in mechanobiology, tissue engineering and biomaterials · doi:10.1007/978-981-99-6564-9_2 · Cited by 4
Advancement in translational respiratory research using nanotechnology
Pandey, P., Purohit, D., Chellappan, D. K., Gupta, G., Tambuwala, M. M., Aljabali, A. A. A., Satija, S., & Dureja, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00010-8 · Cited by 4
Strategies for Enhanced Drug Targeting to Inflamed Lungs: Novel Perspectives
Pardeshi, C. V., Pardeshi, S. R., & Naik, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_12 · Cited by 4
Current Therapeutic Strategies and Possible Effective Drug Delivery Strategies against COVID-19
Dastidar, D. G., Ghosh, D., Ghosh, S., & Chakrabarti, G. (2022) · Current Drug Delivery · doi:10.2174/1567201819666221004094509 · Cited by 4
Drug delivery system on the base of phospholipid nanoparticles for rifampicin
Sanzhakov, M. A., Prozorovskyi, V. N., Ipatova, O. M., Tikhonova, E. G., Medvedeva, N. V., & Torkhovskaya, T. I. (2013) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20135905585 · Cited by 4
Anjum, M. M., Kumar, S., Arya, D. K., Kanaujiya, S., Pandey, P. K., Singh, S., Agrawal, A. K., & Rajinikanth, P. S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126124 · Cited by 3
PATIL, M., & Patel, P. H. (2023) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2023v15i1.46611 · Cited by 3
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3
Drug Delivery Systems Based on Various Natural Polymers for Lung Diseases
Singh, S., Arora, K., Dua, K., & Singh, L. (2023) · Springer eBooks · doi:10.1007/978-981-19-7656-8_3 · Cited by 3
Sharma, G., Pund, S., Govindan, R., Nissa, M. U., Biswas, D., Middha, S., Ganguly, K., Mahesh, P. A., Banerjee, R., & Srivastava, S. (2023) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0074 · Cited by 4
Development and Characterization of Nanocarrier Systems for the Delivery of Antitubercular Drugs
Ribeiro, R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/b6v3-t472 · Cited by 3
Recent approaches of proliposome-based dry powder inhalation for pulmonary delivery
Havelikar, U. A., Magar, S. B., Teharke, A. K., & Chaudhari, N. B. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108053 · Cited by 2
Bya, L.-A., Dinh, T. N., Penoy, N., Sacré, P., Bottero, B., Cataldo, D. D., Hendrickx, E., Conrard, L., Évrard, B., Piel, G., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115035 · Cited by 2
D’Angelo, D., Glieca, S., Flammini, L., Bertoni, S., Bianchera, A., Quarta, E., Forbes, B., Sonvico, F., & Buttini, F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060684 · Cited by 2
Liposomes for the Management of Allergic Airway Diseases
Chandran, C. S., Sajayan, K., Anjana, P. K., Swathy, K. K., Raj, A., & AlSahi, A. M. M. (2024) · Springer eBooks · doi:10.1007/978-981-97-1953-2_9 · Cited by 2
Ruiz, V. H., Encinas-Basurto, D., Alarcon, N. O., Eedara, B. B., Fineman, J. R., Black, S. M., & Mansour, H. M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00432 · Cited by 2
Self-citation(2012) · Pediatric Pulmonology · doi:10.1002/ppul.22681 · Cited by 2
Liposome as a versatile carrier for pulmonary drug delivery
Kumar, D. K., Gupta, S. L., Rajni, Bhatia, J. K., Kirti, K., & Faiyazuddin, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00005-0 · Cited by 1
Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives
Vatankhah, A., Moghaddam, S. H., Rahmanian, M., Khosropanah, S., Oroojalian, F., Kesharwani, P., & Sahebkar, A. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02728-0 · Cited by 1
The rifampicin drug delivery system based on phospholipid nanoparticles
Sanzhakov, M. A., Prozorovskyi, V. N., Ipatova, O. M., Tikhonova, E. G., Medvedeva, N. V., & Torkhovskaya, T. I. (2014) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750814020127 · Cited by 1
Aerosol Therapy Development and Methods of Increasing Nebulization Effectiveness
Matuszak, M., Ochowiak, M., & Doligalski, M. (2018) · Lecture notes on multidisciplinary industrial engineering · doi:10.1007/978-3-319-73978-6_19 · Cited by 1
Dry Powder Aerosol Nanocomposite Microparticles for the Treatment of Pulmonary Diseases
Wang, Z. (2016) · doi:10.23860/diss-wang-zimeng-2016 · Cited by 1
Alhariri, M. (2013) · Lu Zone Ul (Laurentian University)
Methods of Preparation of Nanoparticle Formulations for the Treatment of COPD
Paul, S. R., Nayak, S. K., Anis, A., & Pal, K. (2017) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-5225-3023-7.ch011
Sibeko, M. A., Agbakoba, V. C., Nkomo, J., & Hlangothi, S. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820054-4.00014-8
Acosta, M. F. (2019) · UA Campus Repository (The University of Arizona)
Methods of Preparation of Nanoparticle Formulations for the Treatment of COPD
Paul, S. R., Nayak, S. K., Anis, A., & Pal, K. (2021) · IGI Global eBooks · doi:10.4018/978-1-7998-8591-7.ch017
Nanoparticles in Chronic Respiratory Diseases
Raja, A., Mahendiratta, S., Singh, H., Shekhar, N., Prakash, A., & Medhi, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_8
Inhalation Therapy in Pulmonary Tuberculosis
Manning, T. J., Thomas-Richardson, J., Johnson, C. W., Patel, K., Thaker, Y., Thomas-Richardson, G., Philips, D., & Wylie, G. (2023) · Integrated science · doi:10.1007/978-3-031-15955-8_16
Glimpse on Proliposomal Dry Powder Inhaler: Novel Platform Technology for Pulmonary Drug Delivery
Dhanje, S. V., Waghmode, N., Jadhav, P. D., Velhal, A. B., & Redasani, V. K. (2023) · International Journal of All Research Education & Scientific Methods · doi:10.56025/ijaresm.2023.1201242118
Innovative Dual Combination Cospray-Dried Rock Inhibitor/ l -Carnitine Inhalable Dry Powder Aerosols
Acosta, M. F., Encinas-Basurto, D., Abrahamson, M. D., Eedara, B. B., Hayes, D., Fineman, J. R., Black, S. M., & Mansour, H. M. (2024) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.4c00063
Self-citationRole of vesicular nanocarriers for the treatment of tuberculosis
Saren, B. N., Dighe, S., Jha, S., & Jain, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24035-5.00005-0
Therapeutic Applications of Proliposomes in Pulmonary Drug Delivery
Elhissi, A. M. A., Elkhalifa, D. H., Khan, I., & Ahmed, W. (2025) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-319-01297-1_4
An overview of dry powder inhaler production methods
Aygüler, C. İ., Dağıstan, Ö. A., & Yıldız-Peköz, A. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1712419
Bioactive‐Based Nanocarriers for the Treatment of Lung Disorders
Ganguly, S. C., Giri, S., & Kundu, M. (2025) · Wiley eBooks · doi:10.1002/9781394287345.ch18
Advancing chronic obstructive pulmonary disease treatment with inhaled nano-carrier systems
Shah, K. A., Khan, M. N., Musonye, H. A., Ali, T., Razzaq, A., Iqbal, H., & Cui, J.-H. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100424
Particulate systems for lung delivery of pyrazinamide for tuberculosis treatment
Pham, D. D. (2014) · theses.fr (ABES) · doi:10.70675/03166a20zd23bz4ca1z8706z5d3f89b3c5dd
Shafi, H., Muralidharan, P., Encinas-Basurto, D., & Mansour, H. M. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00181
Self-citationHarnessing Inhaled Nanoparticles for Enhanced Pharmacokinetics and Pharmacodynamics of Drugs
Arun, B., Matcha, S., & Rao, G. G. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676439-00250
Haloi, P., Aggarwal, S., Sharma, S. K., & Kapoor, D. U. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108990
Metadata
- Authors
- Willis, L., Hayes, D., & Mansour, H. M.
- Affiliations
- University of Kentucky (US)
- Nationwide Children's Hospital (US)
- Corresponding author
- Mansour, Heidi M.
- Venue
- Lung
- Published
- 2012-01-25
- Volume
- 190
- Issue
- 3
- Pages
- 251-262
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W2081617033
- Cited by
- 148
- References
- 117
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 11 · 2021: 7 · 2020: 14 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 8 · 2014: 22 · 2013: 11 · 2012: 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- lipospheres, proliposomes, dry powder inhaler, phospholipids, pulmonary surfactant, controlled drug release, formulation stability, lung disease, lung cancer, tuberculosis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, pulmonary infection
- MeSH terms
- Administration, Inhalation, Aerosols, Pharmaceutical Preparations, Humans, Liposomes, Lung, Lung Diseases, Powders, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
